Progenics Pharmaceuticals Inc. (PGNX)

5.77
NASDAQ : Health Technology
Prev Close 5.63
Day Low/High 5.57 / 5.84
52 Wk Low/High 3.42 / 6.31
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 86.42M
Market Cap 486.56M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Interesting PGNX Put And Call Options For July 19th

Interesting PGNX Put And Call Options For July 19th

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the July 19th expiration.

These 3 Biotech Stocks Are Moving Closer to Profitability

These 3 Biotech Stocks Are Moving Closer to Profitability

Here are updates on small biotech/biopharma names I have profiled before.

Interesting PGNX Put And Call Options For November 15th

Interesting PGNX Put And Call Options For November 15th

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the November 15th expiration.

My Post-Earnings Assessment of 2 Biotech Stocks

My Post-Earnings Assessment of 2 Biotech Stocks

Let's look at a couple of companies we have covered on these pages before.

3 Small Biotechs to Watch as Earnings Season Winds Down

3 Small Biotechs to Watch as Earnings Season Winds Down

One already is up nicely on its results, while the other two should issue reports of interest in the next few days.

First Week Of March 15th Options Trading For Progenics Pharmaceuticals

First Week Of March 15th Options Trading For Progenics Pharmaceuticals

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the March 15th expiration.

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

Interesting PGNX Put And Call Options For August 16th

Interesting PGNX Put And Call Options For August 16th

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the August 16th expiration.

Here Are 3 Small-Cap Names for Biotech Investors to Consider

Here Are 3 Small-Cap Names for Biotech Investors to Consider

We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Progenics Pharmaceuticals Becomes Oversold (PGNX)

Progenics Pharmaceuticals Becomes Oversold (PGNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

My Options Strategy for These 2 Biotech Stocks

My Options Strategy for These 2 Biotech Stocks

It's weeks like this that I'm glad I have some 'dry powder' to deploy.

First Week Of May 2019 Options Trading For Progenics Pharmaceuticals (PGNX)

First Week Of May 2019 Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the May 2019 expiration.

Interesting PGNX Put And Call Options For January 2021

Interesting PGNX Put And Call Options For January 2021

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the January 2021 expiration.

Buy Struggling Progenics and Dynavax Here

Buy Struggling Progenics and Dynavax Here

Both biotech stocks are at or near 52-week lows, but don't deserve to be.

RSI Alert: Progenics Pharmaceuticals (PGNX) Now Oversold

RSI Alert: Progenics Pharmaceuticals (PGNX) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Two Hundred Day Moving Average Cross - PGNX

Notable Two Hundred Day Moving Average Cross - PGNX

In trading on Monday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $7.18, changing hands as low as $7.15 per share.

Seeking Bargains on Last Week's Selloff

Seeking Bargains on Last Week's Selloff

These 5 stocks are a good value on this weakness.

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

3 Stocks to Consider Now

3 Stocks to Consider Now

Two things usually occur right after earnings season winds down.

Relative Strength Alert For Progenics Pharmaceuticals

Relative Strength Alert For Progenics Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of PGNX September 21st Options Trading

First Week Of PGNX September 21st Options Trading

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the September 21st expiration.

First Week Of February 2019 Options Trading For Progenics Pharmaceuticals (PGNX)

First Week Of February 2019 Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2019 expiration.

Strategies for 3 Biotechs Before FDA Action

Strategies for 3 Biotechs Before FDA Action

Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

First Week Of PGNX July 20th Options Trading

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the July 20th expiration.

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

These names are moving up or down in a big way ahead of releasing drug-trial results.

4 Names to Watch Ahead of Cancer Conference

4 Names to Watch Ahead of Cancer Conference

American Society of Clinical Oncology will see presentations from dozens of companies.

4 Names to Buy in a Refreshed Biotech Space

4 Names to Buy in a Refreshed Biotech Space

After a strong week for the biotech sector, these names have potential catalysts to move shares.

TheStreet Quant Rating: D (Sell)